FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like Heron Therapeutics Soars on Positive Phase III Results March 18, 2018 Despite Spike, Why Investors Should Still Avoid MannKind Like the Plague January 30, 2018 5 Healthcare Systems to Launch New Generic Drug Company January 17, 2018
